Immune Therapy Articles & Analysis
23 news found
Compared with conventional formulations, microspheres enable long-term and stable drug release in the body, making them a perfect choice for immunization, gene therapy and tumor chemotherapy. “With the increasing demand for targeted drug delivery and minimally invasive procedures, there is a growing need for high-quality polymer microspheres and raw ...
(NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced promising new in vivo combination data that support the potential of the company’s novel gaseous nitric oxide (gNO) therapy to treat various types of solid tumors in combination with immune checkpoint inhibitor (ICI) ...
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. ...
This further expands the GlycoConnect™ ADC tool kit by significantly enhancing the versatility across cytotoxic payloads and supports further expansion into antibody-based targeted gene therapy and immune cell engager ...
“This advisory board brings together invaluable expertise in hematological and solid cancers as well as the biology of NK cells and their application to further the development of our novel and highly potent innate immune cell-engaging therapies.” Dr. Fehniger of Washington University School of Medicine added, “This is an exciting time for ...
The International Society for Cell & Gene Therapy (ISCT) and The National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT) led by the Georgia Institute of Technology are pleased to launch the first joint-training program of our partnership, Workforce Development in Biomanufacturing – A Global Partnership with ISCT and CMaT. ...
(NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune therapies for cancer and infectious diseases. OPKO acquired ModeX for $300 million in OPKO common stock. ...
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), notes findings by a team of physician-scientists led by principal investigator Dr. Amir Jazaeri, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and reported at the annual meeting of Society of Gynecologic Oncology (SGO) in Phoenix, AZ, that a subset of patients with ovarian clear ...
MB097 is a fully defined LBT comprising a consortium of bacteria at the core of Microbiotica’s clinical microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy. MB310 is a fully defined LBT comprising a consortium of bacteria for the treatment of Ulcerative Colitis (UC) identified as being linked to remission in a UC ...
(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Rutgers, The State University of New Jersey. The collaboration will focus on the discovery and development of novel ...
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. ...
Kovach M.D, commented that “recent advances in therapy with immune checkpoint inhibitors have been a true breakthrough in the development of more effective and less toxic treatment for many cancers. ...
In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS. ...
Orally available Alphataxin, is the first and only drug in development to increase formation of CD4+ helper T cells. Immune checkpoint inhibitor therapy, the vanguard of cancer therapy, promotes the ability of CD8+ T cells to kill tumor cells. ...
Also, this conference was a highlight such as CD80-CD28 mechanism, NK cell therapy, bone marrow-derived immune cell and GI-101 is centered among the various immune checkpoint ...
"In situations where conventional testing may miss key mutations that could match patients with targeted therapies, NGS technology is vital to make these connections and advance precision medicine. ...
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, ...
With a recently closed $60 million funding round, the acquisition of software company Dropprint Genomics, and additions to its leadership team, immune profiling firm Immunai is looking to expand its functional genomics capabilities to more directly inform immune therapy development and application. ...
ByImmunai
Both the acquisition and new hires will advance the company’s work in single cell functional genomics with the goal of better supporting discovery, prioritization, and development of new therapies and drug combinations. Dropprint Genomics, a Y Combinator-backed startup, has developed computational infrastructure to conduct single-cell sequencing at scale, developed ...
ByImmunai
Today, Immunai launches out of stealth to map the entire immune system for better detection, diagnosis, and treatment of disease. ...
ByImmunai